← Back to Search
Activation Of The PD-1 Pathway Contributes To Immune Escape In EGFR-driven Lung Tumors.
E. Akbay, S. Koyama, J. Carretero, Abigail Altabef, J. Tchaicha, C. Christensen, O. Mikse, A. Cherniack, E. Beauchamp, T. Pugh, M. Wilkerson, P. Fecci, M. Butaney, J. Reibel, Margaret Soucheray, Travis J Cohoon, P. Janne, M. Meyerson, D. Hayes, G. Shapiro, Takeshi Shimamura, L. Sholl, S. Rodig, G. Freeman, P. Hammerman, G. Dranoff, K. Wong
Published 2013 · Biology, Medicine
Download PDFAnalyze on Scholarcy
UNLABELLED The success in lung cancer therapy with programmed death (PD)-1 blockade suggests that immune escape mechanisms contribute to lung tumor pathogenesis. We identified a correlation between EGF receptor (EGFR) pathway activation and a signature of immunosuppression manifested by upregulation of PD-1, PD-L1, CTL antigen-4 (CTLA-4), and multiple tumor-promoting inflammatory cytokines. We observed decreased CTLs and increased markers of T-cell exhaustion in mouse models of EGFR-driven lung cancer. PD-1 antibody blockade improved the survival of mice with EGFR-driven adenocarcinomas by enhancing effector T-cell function and lowering the levels of tumor-promoting cytokines. Expression of mutant EGFR in bronchial epithelial cells induced PD-L1, and PD-L1 expression was reduced by EGFR inhibitors in non-small cell lung cancer cell lines with activated EGFR. These data suggest that oncogenic EGFR signaling remodels the tumor microenvironment to trigger immune escape and mechanistically link treatment response to PD-1 inhibition. SIGNIFICANCE We show that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory cytokines. These findings indicate that EGFR functions as an oncogene through non-cell-autonomous mechanisms and raise the possibility that other oncogenes may drive immune escape.
This paper references
Sign up to receive free email-alerts
The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity
J. Barretina (2012)
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
H. Ji (2006)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from
I. Akalay (2013)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Hallmarks of Cancer: The Next Generation
M. Roizen (2012)
Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells.
C. Kudo-Saito (2009)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
D. Ercan (2012)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
A. Parsa (2007)
Deciphering the Key Features of Malignant Tumor Microenvironment for Anti-cancer Therapy
B. Shang (2012)
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
Zhao Chen (2010)
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting
H. Matsushita (2012)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
B. Chen (2013)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
A. Sharpe (2007)
American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from Published OnlineFirst September 27
Tumor immune escape by the loss of homeostatic chemokine expression
A. Pivarcsi (2007)
The PD‐1 pathway in tolerance and autoimmunity
Loise M. Francisco (2010)
PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis
X. Huang (2009)
Cancer immunoediting: from immunosurveillance to tumor escape
Gavin P Dunn (2002)
The polarization of immune cells in the tumour environment by TGFβ
R. Flavell (2010)
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
D. Li (2007)
Restoring function in exhausted CD8 T cells during chronic viral infection
D. Barber (2006)
Cancer Discovery Esra A. Akbay, Shohei Koyama
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
M. Imielinski (2012)
American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from Published
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers
K. Yonesaka (2008)
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis.
I. Akalay (2013)
The tumor microenvironment and its role in promoting tumor growth
T. Whiteside (2008)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
W. Zhou (2009)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
K. Ohashi (2013)
of Potential Confl icts of Interest
Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.
D. Zaiss (2013)
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Z. Weaver (2012)
Lineage relationship and protective immunity of memory CD8 T cell subsets
E. Wherry (2003)
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
S. Gao (2007)
Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism
Gabriel A Frampton (2011)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco (2009)
Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
K. Shedden (2008)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)
This paper is referenced by
Therapeutic Advances in Respiratory Disease
Joline Si Jing Lim (2016)
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
Maria I. Toki (2018)
Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance
A. Passarelli (2020)
The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer
Y. Zhang (2019)
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Caglar Cekic (2014)
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression.
Pamela Abdayem (2020)
Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma
Da-Liang Ou (2018)
Circulating CD137+CD8+ T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patients
J. Nong (2019)
High PD‐L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta‐analysis of the literature
G. Troiano (2019)
Prognostic value of PD‐L1 expression in combination with CD8+ TILs density in patients with surgically resected non‐small cell lung cancer
H. Yang (2018)
The tumour microenvironment of pituitary neuroendocrine tumours
P. Marques (2020)
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
B. K. Chaganty (2018)
MUC1-C INTEGRATES PD-L1 INDUCTION WITH REPRESSION OF IMMUNE EFFECTORS IN NON-SMALL CELL LUNG CANCER
Audrey Bouillez (2017)
Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
M. Sanmamed (2014)
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors
Adrian M. Seifert (2016)
The lung microenvironment: an important regulator of tumour growth and metastasis
N. Altorki (2018)
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic
K. Oguejiofor (2017)
Programmed cell death ligand 1 expression in cytologic and surgical non–small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations
P. Mei (2019)
Potential predictive value of JAK2 expression for Pan-cancer response to PD-1 blockade immunotherapy
J. Peng (2018)
Allosteric inhibitors of the STAT3 signaling pathway.
Junhong Qin (2020)
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
J. Zhang (2018)
Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
W. J. Kelly (2018)
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Bin-Chi Liao (2017)
Cancer‐Cell‐Intrinsic Mechanisms Shaping the Tumor Immune Landscape
Max D. Wellenstein (2018)
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Robert S Brody (2017)
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer
Dennis O. Adeegbe (2018)
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
S. Xue (2017)
Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy
X. Yan (2017)
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Yu Mei (2016)
Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD‐L1)‐mediated immunosuppression
Q. Xu (2019)
Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings
Mounika U. L. Goruganthu (2020)
DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model
T. Jimbo (2019)See more